Understanding the chain reaction of chronic diseases

Chronic diseases often occur together. Diabetes can damage blood vessels, affecting the heart and kidneys. Managing blood sugar and weight helps. The body produces hormones like insulin and GLP-1 to regulate blood sugar. Consult your doctor to understand the connections between your conditions. Holistic care improves overall health. Small steps can lead to big improvements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9QXZz63
via IFTTT

Read More

Monitor presence of potentially carcinogenic chemical in Ranitidine: DCGI to drug controllers

The DCGI has directed state and UT drug controllers to monitor levels of the potentially carcinogenic NDMA in Ranitidine, an antacid. This action follows concerns about NDMA impurity and recommendations from the Drugs Technical Advisory Board (DTAB). Manufacturers are urged to take risk-based measures, including shelf-life reduction, while ICMR considers a safety study.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nXCUWMv
via IFTTT

Read More

Maker of GLP1 pens scales up for generic debuts

As weight-loss drug sales surge with semaglutide's patent expiration, Gujarat's Shaily Engineering Plastics, an injector pen manufacturer, anticipates significant growth. Its stock has nearly doubled, and the company is doubling its production capacity to 80-85 million pens by fiscal year-end to meet rising domestic and export demands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yGJ7CbR
via IFTTT

Read More

Type 2 Diabetes diet plan: What to eat in a day

Struggling to manage type 2 diabetes through diet? Here’s a simple, balanced full-day eating guide with diabetic-friendly foods to stabilize blood sugar and boost energy levels naturally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u5d6SNx
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic Carbamazepine tablets

Alembic Pharmaceuticals has received final approval from the USFDA for its generic Carbamazepine extended-release tablets (100 mg, 200 mg, and 400 mg), used to treat seizures and nerve pain. The product is a generic version of Novartis’ Tegretol-XR. According to IQVIA, the U.S. market for these tablets is estimated at $71 million for the 12 months ending March 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YlgnM0c
via IFTTT

Read More

Cheaper cancer care therapy earns big bucks for pharma company

ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7auwHQG
via IFTTT

Read More

Does green coffee really help you lose weight? Here's the truth

Green coffee has become popular as a natural weight loss supplement, but how effective is it really? Here's a detailed look.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cmbn25G
via IFTTT

Read More

AIOCD demands strict action against illegal e-pharmacies; raises alarm over inaction by SLAs

The All-India Organisation of Chemists and Druggists raises concerns. It highlights the illegal operation of online pharmacies. These pharmacies violate drug regulations. AIOCD urges the government to take immediate action. They want a crackdown on unlicensed e-pharmacies. The organization calls for the withdrawal of certain regulations. These regulations are being misused. AIOCD emphasizes the need to protect public health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ywhK2O
via IFTTT

Read More

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Three major Indian pharmaceutical companies are recalling drugs in the United States. Sun Pharma is recalling Lisdexamfetamine capsules due to failed dissolution specifications. Lupin is recalling Lisinopril and Hydrochlorothiazide tablets because of product mix-up with Atazanavir and Ritonavir tablets. Dr Reddy's Laboratories is recalling Omeprazole capsules due to the presence of foreign Divalproex Sodium tablets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DZBhVbc
via IFTTT

Read More

Non-alcoholic fatty liver disease: An acute menace and a silent killer

Fatty liver disease is a growing health crisis due to obesity and poor lifestyles. Many individuals are unaware until imaging reveals the issue. A recent screening showed 65% had fatty liver, with normal enzyme levels in many. Teenagers are also affected. Untreated, it can lead to severe liver damage. Early screening and lifestyle changes are crucial for prevention.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qAhPTUK
via IFTTT

Read More

Experts flag UK-India FTA over patent terms, access to drugs

Concerns are mounting in India over the UK-India Free Trade Agreement's potential impact on access to affordable medicines. Experts fear the deal may weaken compulsory licensing norms, a crucial safeguard allowing generic drug production during public health emergencies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p1y7eBh
via IFTTT

Read More

Over 200 cancer day care centres to be established across India: Government

The Union Health Ministry has approved the establishment of over 200 Day Care Cancer Centres (DCCCs) across India for the financial year 2025-26, including 14 in Andhra Pradesh. These centres, prioritized based on ICMR data and state proposals, will be set up in district hospitals or other government facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/roF6Idu
via IFTTT

Read More

Cipla targets $1 bn US revenue in FY27

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics like Advair and Symbicort. The company also plans to launch peptide assets and its first biosimilar in the US by Q2 FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQEjwDN
via IFTTT

Read More

ICMR study found Covid vaccination didn't raise risk of unexplained sudden deaths among young adults: J P Nadda

An ICMR study found no link between COVID-19 vaccination and unexplained sudden deaths among young Indian adults. Instead, factors like past COVID hospitalization, family history, binge drinking, drug use, and intense physical activity were identified as key risks. Another AIIMS study confirmed heart attacks remain the leading cause of sudden deaths, with no post-pandemic pattern shift observed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6N2r4ds
via IFTTT

Read More

Delhi govt directs all pharmaceutical shops to install CCTV cameras to regulate sale of drugs without prescriptions

Delhi government mandates CCTV installation in all pharmacies by July 2025. This aims to stop the sale of low-quality and dual-use medicines without prescriptions. The focus is on high-risk drugs often misused by minors. Regular inspections and special drives will continue. Recent checks on anti-cancer drugs showed compliance with quality standards. These measures promote accountability and ensure drug safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QZYoDGL
via IFTTT

Read More

Duty relief to boost pharma companies' access to UK drug stores

The India-UK Free Trade Agreement is set to significantly benefit India's pharma and medical device industries. Tariff reductions and streamlined regulations will drive growth. Indian companies will gain easier access to the UK market. This will boost exports, especially for generics and biosimilars. The agreement also promotes cross-border research and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tSfPBnd
via IFTTT

Read More

7,000 steps a day may be the new magic number for better health: Lancet Study

A recent study in The Lancet Public Health reveals that walking at least 7,000 steps daily significantly reduces the risk of cardiovascular disease, cancer, type-2 diabetes, dementia, depression, and falls. Even 4,000 steps show health benefits compared to minimal activity. Researchers suggest 7,000 steps is a more achievable goal than 10,000 for improved health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O7DsMKG
via IFTTT

Read More

Natco Pharma to buy over 35% in South Africa's Adcock Ingram

Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CVoQfkZ
via IFTTT

Read More

Apollo, Siemens collaborate to advance innovation in liver healthcare

Apollo Hospitals and Siemens Healthineers are collaborating to innovate liver healthcare through research. The partnership focuses on quantitative ultrasound imaging and AI-driven solutions to improve liver disease management. Their joint effort aims to enhance early detection, risk stratification, and monitoring of treatment response, ultimately improving patient outcomes and quality of life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q9NfDA7
via IFTTT

Read More

Natco Pharma offers to acquire nearly 36% stake in Adcock Ingram in Rs 2,100-cr deal

Natco Pharma has made a firm offer to acquire nearly 36% stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore. This acquisition will provide Natco Pharma with a strong entry into the Southern African market and expand its footprint in a growing emerging market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IHrlhRp
via IFTTT

Read More

Biocon Biologics launches product for autoimmune diseases in Australia

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating autoimmune diseases like rheumatoid arthritis. Marketed through Generic Health, Nepexto aims to broaden patient access in the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZeVsntL
via IFTTT

Read More

Civil society organisations urge govt to scrap animal testing in biosimilar development

Civil society organizations are urging the health ministry to eliminate animal studies in biosimilar development to lower production costs and expedite the process. They emphasize that removing these tests will enhance affordability and uphold ethical standards. The government is revising biosimilar regulations, potentially restricting animal use and prioritizing in-vitro studies, aligning with global standards to ensure safety and efficacy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PenTDGJ
via IFTTT

Read More

PLI scheme for bulk drugs led to import savings of Rs 1,362 cr: Govt

India's PLI scheme for bulk drugs is showing positive results. It has reduced pharma raw material imports by Rs 1,362 crore until March 2025. The scheme spurred domestic manufacturing and exports. Investment under the scheme has already surpassed initial commitments. The government has also initiated a PLI Scheme for Pharmaceuticals with a total budgetary outlay of Rs 15,000 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QJzVsyj
via IFTTT

Read More

Godavari Biorefineries secures Chinese patent for breakthrough anti-cancer molecule

Godavari Biorefineries received a patent from China for its new anti-cancer molecule. The China National Intellectual Property Administration granted the patent. Sathgen Therapeutics, Godavari's biotech division, developed the molecule. The molecule, HYDROXY-1,4-NAPHTHALENEDIONE, shows promise in fighting cancer. In vitro studies showed it inhibits cancer and cancer stem cells. It is effective against breast and prostate cancer cells.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fey3ca6
via IFTTT

Read More

Obesity lab: India becomes ground zero for weight-loss drug race

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are launching innovative anti-obesity medications, while Indian companies gear up to produce affordable generic versions. Government support and incentives further position India as a major exporter of these crucial medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FsK6H18
via IFTTT

Read More

ADIA signs a definitive agreement to invest $200 million in medical devices firm Meril

Abu Dhabi Investment Authority (ADIA) is set to invest $200 million for a 3% stake in medical device maker Meril, valuing the company at $6.6 billion. This investment, pending CCI approval, will support Meril's growth and research efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SehyA24
via IFTTT

Read More

Abu Dhabi Investment Authority to buy 3% stake in Micro Life Sciences for $200 mn

Abu Dhabi Investment Authority (ADIA) is set to acquire a 3% stake in the Indian medical device company, Micro Life Sciences Pvt Ltd (Meril), for USD 200 million. This investment values Meril at USD 6.6 billion, pending regulatory approval from the Competition Commission of India (CCI). Meril plans to use the funds to accelerate growth and strengthen clinical research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rFMbOcD
via IFTTT

Read More

Brookfield, EQT close in on Gland Pharma, but rising stock a pain

The Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XMPWGYU
via IFTTT

Read More

Zydus Life's plans for cancer biosimilar hit a legal hurdle

The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infringement case filed by Bristol Myers Squibb concerning its anticancer drug Opdyta (nivolumab).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q40EjHC
via IFTTT

Read More

Dr Reddy's gets seven observations from USFDA for Andhra plant

Dr Reddy's Laboratories faces scrutiny. The USFDA issued a Form 483 after inspecting their Srikakulam facility. The inspection, which occurred in July 2025, revealed seven observations. These observations relate to potential violations of the Food, Drug and Cosmetic Act. Dr Reddy's plans to address these concerns promptly. The company aims to resolve the issues within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5DHes8o
via IFTTT

Read More

Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway

India is developing a new malaria vaccine. The Indian Council of Medical Research is leading the effort. The vaccine is called AdFalciVax. It targets two stages of the malaria parasite. Preclinical data shows excellent efficacy. The vaccine could prevent infection and reduce transmission. ICMR plans to license the technology to manufacturers. This aims to make the vaccine widely available.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KJ75uly
via IFTTT

Read More

Mind your posture: Doctors cite long hours in front of screen for increasing lifestyle diseases

Young professionals are increasingly facing lifestyle ailments due to prolonged sitting and screen time, leading to a 30-40% rise in muscular, spinal, eye, heart, and mental health disorders. The pressure to stay relevant in an AI-driven workplace exacerbates these issues, causing conditions like Tech Neck and Digital Fatigue Syndrome.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NRZwo7U
via IFTTT

Read More

New dilemma looms for India’s private hospitals: More beds, but few can lie in them

India's private hospital sector faces a potential overcapacity in major cities due to significant upcoming bed additions, even as smaller towns lack sufficient beds. While demand for quality healthcare grows, driven by rising incomes and insurance coverage, analysts caution that this expansion could strain profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DpnW9w0
via IFTTT

Read More

Sprays, pills, creams...ooh, aah, ouch? India’s pain market is now a Rs 16,000 cr giant

India’s pain relief market has exploded post-pandemic, doubling to nearly ₹16,000 crore in just five years. From gels and sprays to pills like Dolo and Zerodol, pain meds are now a daily fix for everything from gym soreness to chronic stress. The shift is lifestyle-driven and increasingly normalised, but experts warn against unchecked self-medication. As the over-the-counter space booms, driven by awareness and ease of access, the line between relief and risk is getting worryingly thin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2tuEaO7
via IFTTT

Read More

Central drugs laboratories find 55 samples to be 'not of standard quality' in June

In June 2025, central drugs laboratories discovered 55 drug samples failing quality standards, while state labs found 130 similarly substandard. The CDSCO regularly posts lists of these and spurious drugs. Additionally, one drug sample each from Bihar and Delhi, and two from Telangana, were identified as spurious, prompting investigations and regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vnuZJlp
via IFTTT

Read More

Kenvue ties up with API to launch India's first Cough Clinics

Kenvue, makers of Benadryl, introduces 'Cough Clinics' in partnership with the Association of Physicians of India. This initiative aims to establish ten Centers of Excellence across India. These clinics will enhance healthcare professionals' knowledge of cough evaluation. The goal is to promote science-backed approaches to treatment. The clinics will offer specialized training and tools for physicians.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H1E9tSQ
via IFTTT

Read More

Torrent Pharma seeks CCI nod to acquire majority stake in JB Chemicals for Rs 19,500 crore

Torrent Pharmaceuticals is looking to acquire J B Chemicals and Pharmaceuticals. The deal is worth Rs 19,500 crore. The company has sought clearance from the Competition Commission of India. After the deal, Torrent will become India's second most valued pharma company. Torrent will acquire a 46.39 per cent stake from Tau Investment. It will also buy 2.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BFv9ajx
via IFTTT

Read More

Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVie Inc. This deal, concerning ISB 2001, is expected to significantly strengthen Glenmark's financial standing and liquidity, reversing a previous net debt.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ibjoY94
via IFTTT

Read More

CORONA Remedies acquires 7 brands from Bayer's pharma division in India

CORONA Remedies has bought seven brands from Bayer's pharmaceutical unit in India. The deal includes Noklot for heart patients. Women's health brands like Fostine and Ovidac are also part of the acquisition. This move allows CORONA Remedies to enter a new heart treatment area. It also strengthens their position in women's healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0AdBOax
via IFTTT

Read More

Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugs

Glenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio and strengthening its branded business. By 2030, the company aims for 70% of its revenue to come from branded products, focusing on dermatology, respiratory, and oncology. A recent deal with AbbVie for its cancer drug ISB 2001 highlights this strategic shift.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ym1bgjE
via IFTTT

Read More

Domestic med-tech companies flag security threat from Chinese devices

Indian medical tech leaders have voiced concerns to the government regarding the security risks associated with importing Chinese healthcare devices. They highlighted potential misuse for surveillance, cyberattacks, and data breaches, urging stricter scrutiny and measures to prevent rerouting via other countries. Manufacturers also seek streamlined regulations and policy support to boost domestic production and achieve self-reliance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yDKMJ4j
via IFTTT

Read More

Biocon Biologics gets USFDA nod for diabetes medication

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It is a rapid-acting insulin analog. The medication will be available in prefilled pens and vials. This approval expands Biocon's insulin portfolio. Kirsty has been available in Europe and Canada since 2022. The US market for Insulin Aspart is significant.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t5qvzBc
via IFTTT

Read More

200% or more? Trump hints at 'very high tariffs' on pharma cos by August 1, says deal with India most likely

US President Trump had earlier suggested pharmaceutical tariffs could reach 200% after a year, incentivizing domestic manufacturing. On Tuesday, he said that an agreement with India was among the most likely.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/68QMApb
via IFTTT

Read More

Manipal Hospitals borrows Rs 5,300 crore from global banks to fund Sahyadri acquisition

Manipal Hospitals is securing ₹5,300 crore from foreign banks. This funding supports its acquisition of Sahyadri Hospitals. Deutsche Bank, Barclays, MUFG, SMBC, and DBS Bank are providing the debt. The total deal is around ₹5,900 crore. Manipal will issue bonds maturing in two years. An IPO is planned for 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0s8CIQY
via IFTTT

Read More

HLL Lifecare reports annual condom production of 221.7 cr

HLL Lifecare, a Kerala-based PSU, produces 221.7 crore condoms annually, solidifying its position as a leading global manufacturer. With eight factories across India, HLL significantly contributes to the nation's family welfare programs. Established in 1966 to address population growth, HLL has expanded beyond contraceptives, producing diagnostic kits, pharmaceuticals, and Ayurvedic medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aypom2c
via IFTTT

Read More

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

The National Pharmaceutical Pricing Authority (NPPA) has revised the prices of 71 essential drug formulations, encompassing treatments for metastatic breast cancer, diabetes, peptic ulcers, and severe infections. This revision aims to ensure affordability and accessibility of these crucial medicines. Retailers are now mandated to display the updated price lists for transparency and consumer awareness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/V3DSHNF
via IFTTT

Read More

Marengo Hospitals lines up ₹150 cr for western foray

Marengo Asia Healthcare, supported by Samara Capital and others, is set to expand into Maharashtra and Rajasthan with a ₹150 crore investment. The multi-specialty hospital platform aims to double its bed capacity from 1,500 to 3,000 by next year through strategic acquisitions and expansion of existing facilities, solidifying its position as a top healthcare leader in North and West India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jy5v3Ix
via IFTTT

Read More

Temasek building on India strategy with special focus on healthcare

Singapore's Temasek is significantly expanding its healthcare investments in India, prioritizing scalable and specialized platforms. Their recent backing of Manipal Hospitals' acquisition of Sahyadri Group demonstrates this strategy, creating a stronger presence in western India. Temasek aims to enhance accessibility and quality in underserved markets, focusing on profitable growth and strategic acquisitions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ze9VfyB
via IFTTT

Read More

Sun Pharma settles litigation with Incyte Corp

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, leading to the dismissal of pending litigation in the US. Incyte has granted Sun a non-exclusive license for oral deuruxolitinib for specific non-oncology indications, including alopecia areata, in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qHV6xcw
via IFTTT

Read More

Aayush Wellness expands nutraceutical product portfolio

Aayush Wellness introduced a new capsule for cognitive function. The company expands its nutraceutical line to address memory and focus issues. They aim to tap into the growing Indian nutraceutical market. Naveena Kumar highlights brain health's importance. Aayush Wellness recently entered tele-consultation and diagnostic testing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gzFLkZp
via IFTTT

Read More

Phase-3 clinical trial enrolment for India's first dengue vaccine to be completed by October: ICMR

India's DengiAll vaccine trial is nearing completion. ICMR scientists anticipate enrolling 10,500 participants by October across 20 Indian centers. The phase III trial assesses the Panacea Biotec's one-shot dengue vaccine. Initial trials showed no safety concerns. Participants will be monitored for two years to evaluate efficacy. This is a crucial step as India currently lacks a licensed dengue vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/54vZpRP
via IFTTT

Read More

Cipla eyes entry into India's weight management market amid rising demand and global competition

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CnbNVQU
via IFTTT

Read More

India's Ayush 'innovations' featured in WHO's brief on AI in traditional medicine

The WHO has lauded India's integration of Artificial Intelligence (AI) with traditional medicine systems like Ayush, acknowledging the country's efforts in a technical brief. This recognition follows India's proposal, leading to WHO's roadmap for AI in traditional medicine. India is using AI to advance Ayush systems through digital platforms, preserving traditional knowledge and promoting global healthcare integration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dphJrXa
via IFTTT

Read More

India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report

Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3kq04eV
via IFTTT

Read More

Wockhardt exits US generics biz to focus on drug discovery

Wockhardt is set to exit its loss-making US generics business to prioritize innovation, focusing on new antibiotic drug discovery and its biologics portfolio in insulin. The company has initiated voluntary liquidation for its US subsidiaries under Chapter 7 of the US Bankruptcy Code. This strategic shift allows Wockhardt to concentrate on high-impact areas and long-term value creation through scientific advancements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rc26b7Z
via IFTTT

Read More

Biosimilars to usher new growth, lead $1 trillion drug exports by 2030

India's pharmaceutical industry is targeting $1 trillion in drug exports by 2030, with biosimilars expected to be a major growth driver. The biosimilars market could exceed $60 billion by 2030, supported by Indian firms investing in biologics and advanced markets. Achieving this ambitious goal requires collaboration and a focus on innovation-driven categories.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pyYO9Eq
via IFTTT

Read More

Pharmexcil flags export disruption risk due to COPP mandate; seeks urgent review

Pharmaceutical Export Promotion Council of India wants Central Drugs Standard Control Organisation to rethink its online Certificate of Pharmaceutical Product submission rule. The council fears this could hurt India's drug exports, especially to Rest of World markets. They worry about delays in approvals. Pharmexcil has asked the Ministry of Health & Family Welfare and CDSCO to talk with exporters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WDQKnfL
via IFTTT

Read More

7 daily habits that silently damage your kidneys

Your kidneys quietly work to filter waste and balance your body’s fluids—but some everyday habits may be putting them at risk without you realising it. Here are 7 common behaviours that could be harming your kidney health over time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NcHa5Ke
via IFTTT

Read More

Adani to create world-class, affordable, AI-first healthcare ecosystems

Gautam Adani unveiled plans for an AI-driven healthcare ecosystem in India, emphasizing affordability and scalability. He highlighted the need for a system-wide redesign, citing low back pain as a major disability. Adani announced Adani Healthcare Temples with Mayo Clinic's guidance, focusing on integrated care, technology, and skilled professionals to address healthcare gaps.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5sCUYaj
via IFTTT

Read More

PGIMER doctors perform India's first robot-assisted vasovasostomy

Doctors at PGIMER Chandigarh have achieved a groundbreaking feat by successfully performing India's first robot-assisted vasovasostomy. The urology team, led by Dr. Aditya Prakash Sharma, used the da Vinci Surgical System for enhanced precision in the male infertility surgery. This innovative approach offers new hope for couples seeking natural conception after vasectomy, marking a significant advancement in andrology and microsurgery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hQFxpN1
via IFTTT

Read More

Ichnos Glenmark, AbbVie ink USD 2-bn licensing deal for commercialisation of investigational asset

Glenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targeting cancer and autoimmune diseases. The deal, potentially worth up to USD 2 billion, grants AbbVie exclusive rights in major markets, while Glenmark will focus on emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MqsJ2Ro
via IFTTT

Read More

Lupin signs $50 million licensing deal with Zentiva to commercialise Certolizumab Pegol across global markets

Lupin Ltd has partnered with Zentiva Group to commercialize its biosimilar 'Certolizumab Pegol' across global markets. The agreement grants Zentiva commercialisation rights outside the US and Canada, primarily in Europe and CIS markets. Lupin will receive up to USD 50 million in milestone payments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c5ZStIC
via IFTTT

Read More

Granules India recalls 33,000 bottles of blood lowering medication in US

Granules India is recalling over 33,000 bottles of Metoprolol Succinate, a generic blood pressure medication, in the US due to manufacturing issues. The USFDA reported that the India-produced lot failed to meet dissolution specifications during stability studies. This Class II recall, initiated on June 24, indicates a potential for temporary or medically reversible health consequences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aPLj7Zr
via IFTTT

Read More

Pills & Profits: Can India's pharma sector handle Trump's planned 200% tariff dose?

India's pharma sector faces a potential challenge. The US considers high tariffs on drug imports. This could hurt Indian companies' profits and competitiveness. It might also raise medicine prices in America. India relies heavily on the US for pharma exports. Companies may need to explore new markets like Europe and Southeast Asia. The news impacted Indian stock markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3eP5Za6
via IFTTT

Read More

Pharma lobby flags 'cumbersome' export rule, seeks change

Pharma lobby groups are urging for changes to the centralized no-objection certification (NOC) for drug exports due to a significant export decline. The requirement for approvals from importing countries or Indian regulators has increased trade diversions. Industry experts are calling for a review of the provision, citing burdens on exporters and potential stifling of innovation, especially for MSMEs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8D1GLtI
via IFTTT

Read More

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

Nectar Lifesciences will sell its active pharmaceutical ingredients, formulation, and menthol business assets to Ceph Lifesciences for ₹1,290 crore. This strategic move involves a Business Transfer Agreement for the core API and formulation business at ₹1,270 crore and an Asset Purchase Agreement for the menthol business at ₹20 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ivWj9Rx
via IFTTT

Read More

Aster DM Healthcare sets sights on smaller cities to expand play, grab top spot

Aster DM Healthcare, after merging with Quality Care India, aims to become India's largest healthcare chain, surpassing Apollo Hospitals. Fueled by Blackstone's backing, Aster plans to increase bed capacity to 13,600 and expand into central India. The company anticipates improved margins through supply chain optimization and increased occupancy, targeting a 23-24% EBITDA margin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CVQ36Z0
via IFTTT

Read More

Delhi HC upholds order to restrain Rajasthan Aushdhalaya from making and selling medicines under Liv-333 name

The Delhi High Court has upheld a previous order restraining Rajasthan Aushdhalaya from selling medicines under the name Liv-333 or similar names, due to trademark infringement of Himalaya's Liv.52. The court found Rajasthan Aushdhalaya's adoption of 'Liv-333' as intentionally similar to capitalize on Himalaya's established reputation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Bo5pOHQ
via IFTTT

Read More

Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course

The Indian Medical Association (IMA) has strongly criticised the Maharashtra Medical Council's (MMC) recent notification allowing homeopaths to prescribe modern medicines after a brief pharmacology course. IMA views this as misleading to patients and a dilution of modern medical practices. They highlight existing legal challenges and a stay order from the Bombay High Court, seeking expedited resolution.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q7HO9ik
via IFTTT

Read More

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These are biosimilars of Denosumab. Vevzuo addresses skeletal events in adults with advanced malignancies. Evfraxy treats osteoporosis and bone loss. This approval follows a similar authorization from the European Commission. It allows commercialization across the EU and EEA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CScevDN
via IFTTT

Read More

Union Health Minister JP Nadda, Delhi CM Rekha Gupta flag off Ayushman Bharat registration vans in New Delhi

Union Minister JP Nadda and Delhi CM Rekha Gupta launched Ayushman Bharat registration vans in New Delhi. Nadda criticized AAP for not utilizing allocated funds for the scheme. He praised Ayushman Arogya Mandir, contrasting it with AAP's Mohalla Clinics. Rekha Gupta and ministers inaugurated Ayushman Arogya Mandirs in Delhi. Ashish Sood distributed Ayushman Bharat cards to senior citizens in Janakpuri.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pz4MjSQ
via IFTTT

Read More

DRDO, AIIMS-Rishikesh ink MoU for clinical trials in field of biomedical devices

DRDO's Defence Institute of Physiology and Allied Sciences (DIPAS) and AIIMS, Rishikesh, have partnered to conduct clinical trials and advanced research. The collaboration aims to develop biomedical devices and supplements enhancing human performance in extreme environments. This joint effort will focus on creating products and technologies to mitigate the adverse effects of such environments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R4XrpWa
via IFTTT

Read More

Niti to review concerns over pharma quality

Niti Aayog is addressing growing quality concerns in India's pharmaceutical industry by convening industry experts for discussions. The aim is to analyze the current state, understand challenges, and improve the quality of Indian pharmaceutical products to meet global standards. A meeting chaired by VK Paul will propose recommendations to ensure alignment with international regulations and patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GmwUWSu
via IFTTT

Read More

Lupin launches Ipratropium Bromide nasal spray in US

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, bioequivalent to Boehringer Ingelheim's Atrovent, target rhinorrhea associated with allergies, nonallergic rhinitis, and the common cold. The annual sales for Ipratropium Bromide nasal solution (Atrovent) in the US were approximately USD 63 million, according to IQVIA MAT May 2025 data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PCLqjzw
via IFTTT

Read More

CBI searches premises of Pharmacy Council of India chief in corruption case

The CBI has booked Pharmacy Council of India President Montu M. Patel for alleged corruption and irregularities in pharmacy college approvals, conducting searches at his premises. Investigations revealed manipulated inspections, favouritism towards specific institutions, and electoral manipulation before Patel's presidential election. Approvals were granted despite negative reports, with evidence of bribery and infrastructural deficiencies in several colleges across multiple states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VEXimKg
via IFTTT

Read More

Hassan heart attack death cases: India’s top drugmakers rally behind Covid vaccines

Amid over 20 sudden heart attack deaths in Karnataka’s Hassan district, leading drugmakers have defended Covid vaccines on social media. Industry leaders including Dilip Shanghvi, Pankaj Patel, Satish Reddy, and Samir Mehta stressed there is no scientific link between the deaths and vaccination. The Karnataka health department has formed an expert panel to investigate. The Indian Vaccine Manufacturers Association and the Indian Pharmaceutical Alliance urged the public to trust India’s vaccine safety and rigorous approval process.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yrUVkHO
via IFTTT

Read More

COVID-19 vaccines well-documented, rigorously tested as per regulatory processes: IPA

The Indian Pharmaceutical Alliance (IPA) refuted claims linking COVID-19 vaccines to heart attack deaths, emphasizing their rigorous testing and crucial role in combating the pandemic. IPA Secretary General Sudarshan Jain highlighted the Indian pharmaceutical industry's knowledge-driven nature and its significant contribution to global vaccine production, accounting for 60% of the world's supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VxE9BGk
via IFTTT

Read More

Karnataka CM's remarks on covid vaccines 'factually incorrect,' says Biocon chief Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw refuted Karnataka CM Siddaramaiah's claim. Siddaramaiah linked covid-19 vaccines to heart attack deaths in Hassan. Shaw stated the vaccines followed rigorous safety protocols. She said the vaccines saved lives. The Union Health Ministry dismissed Siddaramaiah's statement. Studies show no link between vaccines and sudden deaths. The ministry cited various factors for cardiac deaths.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/orBn0vj
via IFTTT

Read More

Delhi HC seeks regulator's reply after PIL questions Ozempic, Mounjaro nod

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like Ozempic and Mounjaro. A public interest litigation raised questions about safety data and clinical trials. The court wants the regulator to consult experts and manufacturers. Ozempic is available in the grey market, though not officially sold in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fn2M7o
via IFTTT

Read More

Auriga Research, SFRI ink pact to advance clinical research, AI-driven support for healthcare industry

Auriga Research partners with San Francisco Research Institute. The collaboration focuses on global clinical research. It will promote AI-integrated healthcare solutions. The partnership aims to expand access to wellness products in India, the US, and Africa. SFRI will support regulatory strategy and commercial partnerships. Both organizations will expand their Research Training Program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xCXdjrv
via IFTTT

Read More

Cipla in talks to add new customers for its China factory, executive says

Indian pharmaceutical giant Cipla is exploring at least two new overseas markets for products made at its Chinese manufacturing plant, as it grapples with limited production capacity in India. The company began producing inhalation respule products at its Jiangsu facility in 2024 to supply the U.S., and is now in talks with other countries to expand exports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eEWsRNJ
via IFTTT

Read More

Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and Wegovy

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canada, where patents expire next year. Managing Director Siddharth Mittal sees Canada as a prime opportunity, aiming for potential approval in 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SAtE7h3
via IFTTT

Read More

Apollo Hospitals to spin off digi health, pharmacy business

Apollo Hospitals is demerging its omnichannel pharma and digital health businesses into a new entity, aiming for a separate listing. This move creates India's largest omnichannel pharmacy platform with a revenue target of ₹25,000 crore by FY27. The promoter family will hold approximately 36.5% in the new company, with Shobana Kamineni as the executive chairperson.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yzOGd41
via IFTTT

Read More

Wockhardt activates Zaynich push, eyes global licensing deals

Wockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions in the US and India. The company is exploring out-licensing deals while preparing for potential solo commercialization in key markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AQmcYDl
via IFTTT

Read More

After a robust march, pharma exports slow

India's pharmaceutical exports experienced a modest 1.5% growth in April and May, following a significant 31.2% surge in March driven by year-end targets and anticipation of US tariffs. Despite pricing pressures and regulatory scrutiny, shipments to the US rose 20.4% to $10.5 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U6crY4N
via IFTTT

Read More

Torrent Pharma set to finalise JB Chemicals buyout in 15-18 months

Torrent Pharmaceuticals is set to acquire JB Chemicals & Pharmaceuticals, with the deal expected to finalize in 15-18 months, pending regulatory approvals. The acquisition, primarily debt-funded, aims to enhance Torrent's presence in the Indian market, particularly in high-growth segments like cardiac and gastroenterology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BtDPmXi
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection

Alembic Pharmaceuticals has received final USFDA approval. This approval is for its generic Doxorubicin Hydrochloride Liposome injection. The injection comes in strengths of 20 mg/10 mL and 50 mg/25 mL. It is used to treat ovarian cancer, AIDS-Related Kaposi's sarcoma, and multiple myeloma. The market size for this injection is estimated at USD 29 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CWsE2vP
via IFTTT

Read More

Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation

Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dNEK69B
via IFTTT

Read More

Clear & Legible: Labelling on drug packets to get a booster

Concerns arose regarding medicine labels. Consumers struggled to read expiry dates. The shiny surface of strips posed readability issues. The Drugs Consultative Committee addressed the matter. A sub-committee will examine packaging in detail. They will assess regulations for packaging suppliers. The government considers voice-assisted QR codes. Braille cards on strips are also under consideration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lFbvXEj
via IFTTT

Read More

Torrent Pharma to buy controlling stake in JB Chemicals from KKR for Rs 25,689 crore

Torrent Pharmaceuticals is set to acquire a 46.39% controlling stake in JB Chemicals and Pharmaceuticals from KKR for ₹11,917 crore, valuing JB Pharma at ₹25,689 crore. Following the acquisition, Torrent plans a merger, pending regulatory approvals, and will launch an open offer to public shareholders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vPMNtoa
via IFTTT

Read More

Torrent, JB Chemicals finalising steps for two-stage merger, combine may find place in pharma big 5

Torrent Pharmaceuticals and JB Chemicals & Pharmaceuticals are finalizing merger terms in a two-stage deal. Torrent will first acquire KKR's 47.84% stake in JB Chemicals for approximately ₹13,433 crore, financed by global banks, potentially triggering an open offer. The subsequent merger aims to create synergies, positioning Torrent among India's top five pharma players with a combined value of ₹1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2PNfkOi
via IFTTT

Read More

From pediatrics to cardiac care: Leading Chennai’s healthcare landscape with compassion and cutting-edge innovations

Dr. Mehta’s Hospitals in Chennai has a 92-year legacy. It began as a small nursing home. Now it is a multi-speciality institution. The hospital focuses on pediatric and cardiac care. It also provides comprehensive women’s health services. The hospital has NABH and NABL accreditations. It trains future medical professionals. Dr. Mehta’s aims to provide clinically strong and tech-enabled healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9SlAZRG
via IFTTT

Read More

Eli Lilly to roll out diabetes medicine in prefilled pen

Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The KwikPen offers a convenient, once-weekly administration. It contains four fixed doses. This launch intensifies competition with Novo Nordisk's Wegovy. Mounjaro's dual mechanism may offer superior efficacy. The availability of all six dosage options will support personalized treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yKveCG0
via IFTTT

Read More

Lupin launches generic chronic constipation treatment drug in US

Mumbai-based Lupin Ltd has introduced its generic Prucalopride tablets in the United States. This launch follows approval from the US health regulatory body. The tablets, available in 1 mg and 2 mg strengths, treat chronic idiopathic constipation in adults. These tablets are bioequivalent to Takeda Pharmaceuticals' Motegrity tablets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wL2lOsr
via IFTTT

Read More

Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy

Eli Lilly announced that India’s drug regulator has approved its Mounjaro KwikPen, a pre-filled injector pen for weight loss and diabetes treatment. Previously available only in vials, Mounjaro will now be offered in six dose strengths, enhancing convenience and competitiveness against Novo Nordisk’s newly launched Wegovy, which also features a user-friendly pen format.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MSnrD85
via IFTTT

Read More

Pharma companies may lose licence if drugs fail tests

The health ministry is considering strict actions, including immediate license suspensions, for drugmakers producing substandard drugs. This proposal follows concerns about quality control and aims to safeguard public health. Pharma lobby groups have raised objections, citing technical issues and questioning the standards of government testing laboratories, while advocating for a stronger recall mechanism.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GeNpgHz
via IFTTT

Read More

Lupin gets USFDA nod for generic chronic constipation treatment drug

Lupin Limited has received the United States Food and Drug Administration approval for its generic version of Prucalopride tablets. These tablets are used for treating chronic idiopathic constipation. The approved strengths are 1 mg and 2 mg. This generic medicine is bioequivalent to Takeda Pharmaceuticals' Motegrity tablets. Lupin will manufacture the product at its Goa facility in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UYvFxtq
via IFTTT

Read More

Bharat Biotech, GSK to halve price of malaria vaccine by 2028

Drugmakers Bharat Biotech and GSK will reduce the price of their malaria vaccine, Mosquirix, to $5 per dose by 2028, more than halving the current cost. This price cut, driven by process improvements and expanded production, aims to improve access to the vaccine in sub-Saharan Africa, where malaria deaths are high. Gavi supports the vaccine's rollout in twelve African countries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/M2JmEpV
via IFTTT

Read More

China+1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs

Indian pharmaceutical and biotech sectors are experiencing early benefits from the global shift away from China, driven by the China+1 strategy. Companies are seeing increased conversion of inquiries into pilot projects and small contracts, particularly from large pharmaceutical firms seeking supply chain diversification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A1WoVil
via IFTTT

Read More

Weight-loss drug Wegovy starts at ₹17,345 in India

Novo Nordisk launches Wegovy, a weekly weight-loss injectable, in India. The drug is available in five dosages, costing between Rupees 17,345 and Rupees 26,015. It aims for chronic weight management and reduces cardiovascular risks. Experts highlight its potential despite the price. Mounjaro, another weight-loss drug, is priced lower. Weight-loss drugs are game changers for obese patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FBKQWxD
via IFTTT

Read More

A big fat fight has just broken out in India

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and diabetes rates, with Mounjaro showing significant weight loss in trials. Wegovy boasts cardiovascular benefits and a competitive pricing strategy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oIRKluT
via IFTTT

Read More

Favipiravir drug shows promise against Chandipura virus in preclinical studies by NIV

Favipiravir offers hope against the Chandipura virus. Studies by the National Institute of Virology show promising results. The drug reduces viral load in infected animals. Chandipura outbreaks have occurred in India, affecting children. A major outbreak happened in 2024. Clinical trials on humans are pending. Research is underway for a vaccine. Current treatment focuses on managing symptoms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3G4jsPE
via IFTTT

Read More

Novo Nordisk aims for heavy sales in India with Wegovy

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescription brand sales. Keytruda, a breakthrough anti-cancer drug from MSD India (part of the US Merck group), is currently the No. 1 in prescription brands, with annual revenue exceeding Rs 1,600 crore, according to market sources.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bZer730
via IFTTT

Read More

Sickle cell anaemia test kits priced less than Rs 50 in govt's bid to eradicate the disease

Sickle cell anaemia diagnosis is now more accessible in India. The government reduced the price of diagnostic kits to under Rs 50. ICMR validated 35 point-of-care tests. This follows a health technology assessment. The National Health Mission instructed states to procure kits at lower prices. This initiative supports the National Sickle Cell Elimination Programme.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RBOyZFU
via IFTTT

Read More

ICMR's NIIH develops simple point of care test for haemophilia A, Von Willebrand Disease

A cost-effective point-of-care test kit has been developed in India for early diagnosis of haemophilia A and Von Willebrand Disease, offering a more accessible alternative to expensive lab tests. This innovation, costing just Rs 582 compared to Rs 2,086 for current methods, could detect over 83,000 undiagnosed cases and save the health system approximately Rs 42 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QdPWxjF
via IFTTT

Read More

From pediatrics to cardiac care: Leading Chennai’s healthcare landscape with compassion and cutting-edge innovations

Dr. Mehta’s Hospitals in Chennai has a 92-year legacy. It began as a small nursing home. Now it is a multi-speciality institution. The hospital focuses on pediatric and cardiac care. It also provides comprehensive women’s health services. The hospital has NABH and NABL accreditations. It trains future medical professionals. Dr. Mehta’s aims to provide clinically strong and tech-enabled healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nlP6arJ
via IFTTT

Read More

Amazon launches home diagnostic services in 6 cities through app

Amazon India has launched Amazon Diagnostics, an at-home lab test booking service, integrating it with Amazon Medical alongside Pharmacy and Clinic services. Partnering with Orange Health Labs, the service is available in major cities like Bengaluru, Delhi, Mumbai and Hyderabad, covering over 450 PIN codes. Customers can book tests, schedule appointments, and access digital reports via the Amazon app.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yHpagqk
via IFTTT

Read More

From pimples to peptides: How Gen Z turned the dermatologist into a beauty guru

Urban India witnesses a surge in dermatology clinic visits, driven by teenagers and young adults seeking solutions for everyday skin concerns beyond chronic conditions. Social media influence and access to information fuel this trend, with consumers actively choosing science-backed skincare. This shift reflects a broader movement towards evidence-based self-care, impacting the skincare market and prompting early dermatologist visits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zk3jqNu
via IFTTT

Read More

Deadline diet India's young workforce faces cardiac scare

Young Indians are increasingly facing heart issues. Doctors report a rise in cardiac cases among those in their 20s and 30s. Stress, lack of sleep, and unhealthy lifestyles are major factors. Sedentary jobs and poor diets contribute to the problem. Even post-Covid inflammation increases the risk. Sales of heart-related drugs have significantly increased.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CzwOp8c
via IFTTT

Read More

Emcure Pharma to acquire remaining 20.42% stake in Zuventus Healthcare for Rs 724.9 cr

Emcure Pharmaceuticals will acquire the remaining 20.42% stake in Zuventus Healthcare Ltd from minority shareholders for ₹724.9 crore, a move approved by its board. This acquisition, expected to close in the September quarter of FY26, will make Zuventus a wholly-owned subsidiary. Emcure aims to fully consolidate Zuventus financially, driving long-term value creation and unlocking synergies within its domestic business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fV9J362
via IFTTT

Read More

Stress at work? Doctors see rise in heart diseases among young executives

Young Indians are increasingly facing heart issues. Cardiologists are alarmed by the rising cases in people in their 20s and 30s. Stress, sleep deprivation, and unhealthy lifestyles are major contributors. Hospitals report more young professionals with cardiovascular diseases. Experts suggest early screenings and lifestyle changes. Companies are now offering heart check-ups for employees.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XlhMg1k
via IFTTT

Read More

The Wegovy effect: A weight-loss drug reshapes the lives of teens battling obesity

Facing relentless bullying and health issues linked to obesity, some American teens are turning to Wegovy, a weight-loss drug initially approved for adults. While many see it as a chance for a healthier future, concerns linger about long-term safety and potential side effects. The experiences of four teens highlight both the benefits and challenges of this treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BnSX4bH
via IFTTT

Read More

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly's Mounjaro has seen a positive reception in India, capturing significant sales and market interest since its launch in March. The company is prioritizing meeting the growing demand for the diabetes and weight-loss drug in the country, where obesity and diabetes rates are rising.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MHEYcfC
via IFTTT

Read More

US approves Gilead's twice-yearly injection to prevent HIV

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus. An earlier long-acting HIV prevention shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021 -- costs tens of thousands of dollars per year and has yet to make a major global impact.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tuwbNhZ
via IFTTT

Read More

Global Autism Therapy Framework for 90 crore children: How India cracked 144-year-old world problem,

Pinnacle, an Indian autism therapy network, gains global recognition. It is acknowledged for its innovative, mother-led, and AI-enabled approach. International institutions and organizations are seeking collaborations. Pinnacle's framework is adaptable and inclusive. It focuses on measurable care and dignity-first delivery. The model is designed for diverse languages and geographies. Pinnacle invites global partnerships to expand its reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zWYqiMG
via IFTTT

Read More

6 anti-cancer foods to add to your daily chai

Make your chai time healthier by adding foods known to offer anti-cancer benefits. These simple, everyday ingredients can help fight harmful cells, boost immunity, and support overall well-being while you enjoy your cup of tea.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GU9nDfs
via IFTTT

Read More

With no upgradation plan, several small drug companies may shut operations

Many small pharma companies in India may shut down. They did not meet the deadline for upgrading facilities. This is as per new Good Manufacturing Practices. Only 1,700 out of 6,000 units submitted upgrade plans. Closures could lead to job losses. There are also concerns about potential drug shortages and price increases. The government may initiate audits and regulatory actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ALDiIyo
via IFTTT

Read More

Abbott, MSD Pharmaceuticals ink distribution pact for oral anti-diabetic medicines in India

Abbott and MSD Pharmaceuticals have partnered to distribute oral anti-diabetic medicines in India. Abbott will distribute MSD's sitagliptin, its combination sitagliptin/metformin, and the extended-release version, marketed as Januvia, Janumet, and Janumet XR. This collaboration aims to leverage Abbott's extensive reach to ensure continued access to these diabetes treatments for the large diabetic and pre-diabetic population in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EYXHb27
via IFTTT

Read More

Suraksha Diagnostics to invest Rs 200 cr to set up over 20 centres across east India

Suraksha Diagnostics plans a significant expansion. The company will invest Rs 200 crore. This investment will establish over 20 advanced imaging centers. These centers will be located across eastern India. The expansion aims to improve diagnostic services. It will focus on tier 2 and tier 3 cities. This initiative will enhance healthcare access in smaller towns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5o6KicY
via IFTTT

Read More

Glenmark gets five observations from USFDA for Monroe plant

Glenmark Pharmaceuticals announced that its Monroe, North Carolina manufacturing plant received a Form 483 with five observations from the USFDA following a GMP inspection conducted in June 2025. The company stated that the observations are procedural and don't involve data integrity issues. Glenmark is committed to addressing the concerns and will respond to the USFDA within the required timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6Cainw1
via IFTTT

Read More

Torrent Pharma keen to break into big league

Torrent Pharma, currently seventh in India, is aimingto break into the top three drugmakers within five years through strategic acquisitions. Bolstered by consistent growth in the Indian market, the company plans further investments following past deals like Curatio Healthcare. Expansion includes doubling its medical representatives to 7,000 for better market reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fZeT3gD
via IFTTT

Read More

US pharma bets big on China to snap up potential blockbuster drugs

U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CFk64zZ
via IFTTT

Read More

Zydus Healthcare appoints Swati Dalal MD

Zydus Lifesciences Ltd. has appointed Swati Dalal as an additional director and Managing Director of its subsidiary, Zydus Healthcare Ltd., effective June 16, 2025, for a five-year term. Dalal brings over 30 years of experience, most recently serving as Managing Director of Abbott India Ltd. Her career includes leadership roles at Wockhardt Nutrition, Boots, Knoll, Solvay, and Abbott.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nZ4AphT
via IFTTT

Read More

Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler

Lupin Limited partners with Sino Universal Pharmaceuticals. They will commercialize Tiotropium dry powder inhaler in China. This inhaler treats Chronic Obstructive Pulmonary Disease. Sino Universal will seek regulatory approvals. Lupin will manufacture the product. This collaboration expands Lupin's presence in China. It aims to improve respiratory disease treatment. The partnership focuses on providing high-quality healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zq8uATM
via IFTTT

Read More

Online pharmacies could face stricter check-ups

Amid rising concerns over unverified prescriptions and a surge in online pharmacies, the government is intensifying regulation and scrutiny on platforms promising medicine delivery within minutes. Complaints regarding bypassed safeguards like age verification have prompted this action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MY96ZRe
via IFTTT

Read More

Kirti Ganorkar: Why the veteran insider is the right dose for Sun Pharma

Kirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, who remains Executive Chairman. This transition marks the culmination of Sun Pharma's succession plan, as Ganorkar steps into the role amidst a challenging global market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vtFqsNg
via IFTTT

Read More

Sun Pharma gets eight observations from USFDA for Halol plant

Sun Pharma announced that the USFDA issued a Form 483 with eight observations after inspecting its Halol manufacturing plant in Gujarat. The USFDA conducted a Good Manufacturing Practices (GMP) inspection at the facility from June 2-13, 2025. The Form 483, issued at the inspection's conclusion, highlights conditions that may violate the Food, Drug, and Cosmetic Act and related regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WTN8zrP
via IFTTT

Read More

Delhi HC refuses to halt Sun Pharma’s Pruease tables sales over trademark row

The Delhi High Court has denied RSPL Health's petition to stop Sun Pharmaceutical Industries from selling Pruease tablets, a constipation relief medication. RSPL Health, which sells sanitary napkins under the trademark 'Pro-ease,' claimed trademark infringement. The court dismissed the plea, stating that the products have distinct trade channels and there is no likelihood of confusion among consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KpBfVUR
via IFTTT

Read More

Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the Board

Sun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi will continue as Executive Chairman, focusing on specialty portfolio and long-term strategy. Additionally, Richard Ascroft will succeed Abhay Gandhi as CEO – North America, reporting to Aalok Shanghvi, who takes on additional responsibility for the North America business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vpt4WX8
via IFTTT

Read More

Bharat Biotech, GSK join hands to develop vaccine for severe diarrhoea

Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by Bharat Biotech, including Phase 3 trials and manufacturing. This collaboration aims to address the urgent need for a Shigella vaccine due to rising antimicrobial resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JvfzKWV
via IFTTT

Read More

Pharma body opposes entry curbs on medical representatives, seeks rethink

The Indian Pharmaceutical Alliance (IPA) voices concerns over the government's ban on medical representatives in central hospitals, arguing it hinders knowledge dissemination and patient care. IPA urges a structured engagement model, citing potential impacts on pharmaceutical growth, job losses, and the introduction of new therapies. They emphasize the role of MRs in sharing crucial information and supporting evidence-based practice.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1F048lB
via IFTTT

Read More

Niti Aayog may prescribe major revamp of AIIMS Delhi

Niti Aayog is expected to propose a major overhaul of AIIMS Delhi, including expanding its clinical services across the NCR to ease infrastructure pressure and allow doctors to focus more on research. A VK Paul-led committee is preparing a blueprint to reform AIIMS to global standards, with plans to utilize other government or private hospital spaces for OPD services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yvkq1uz
via IFTTT

Read More

Glenmark to launch DCGI-approved cancer drug in India

Glenmark Pharmaceuticals is set to introduce zanubrutinib, a cancer treatment drug, in India. This follows approval from the Drugs Controller General of India. The drug, branded as Brukinsa, treats five B-cell malignancies. Glenmark anticipates launching Brukinsa soon, in partnership with BeOne Medicines. This launch expands Glenmark's oncology offerings, providing Indian patients access to a globally recognized and effective therapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CzHT6jQ
via IFTTT

Read More

Advent International to acquire stake in Felix Pharmaceuticals

Advent International is set to invest $175 million in Felix Pharmaceuticals, acquiring a significant minority stake. Felix Pharma, a Dublin-based company, specializes in generic animal pharmaceuticals, particularly for companion animals. With 14 USFDA-approved products and a robust pipeline, Felix aims to expand its global presence with Advent's support and expertise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U54rIpD
via IFTTT

Read More

KKR-backed IVI to buy ART Fertility clinics for $450 million

IVI RMA Global, backed by KKR, is poised to acquire ART Fertility Clinics for $400-450 million, marking a significant expansion into India's burgeoning IVF market. This acquisition will add India to IVI RMA's global presence. The deal highlights the ongoing consolidation in the Indian IVF sector, driven by increasing infertility rates and private equity investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hR5zyCE
via IFTTT

Read More

One cough too many: India's TB fight isn't quite there yet

Despite India's commitment to eliminate TB by 2025, the nation grapples with a significant burden of drug-resistant cases and underreporting. Stories like Anushka's highlight the challenges in accessing effective treatments and the critical need for improved diagnostics, funding, and equitable care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4SC7M3G
via IFTTT

Read More

API prices fall sharply, easing pressure on India's pharmaceutical industry

India's pharmaceutical industry is experiencing relief as active pharmaceutical ingredient (API) prices plummet due to overcapacity and aggressive pricing strategies from Chinese suppliers. Increased domestic API production, driven by government incentives and reduced raw material costs, further contribute to the decline. This trend is expected to continue, boosting profit margins for Indian pharma companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Opcv5mG
via IFTTT

Read More

Dr Reddy’s, Alvotech to co-develop Keytruda biosimilar

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Iu2xyot
via IFTTT

Read More

Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, Europe

Wockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europe. Following a successful pre-NDA meeting with the USFDA, the company plans to file for approval this quarter, aiming for a launch in FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SqXFZtA
via IFTTT

Read More

Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment

Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial cancer treatment with USD 29.5 billion in 2024 sales. The collaboration aims to expedite development and broaden global access to this biosimilar. Both companies will share development, manufacturing costs, and commercialization rights.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qnk9Xb3
via IFTTT

Read More

Avoid crowded places: Union Health Ministry amid surge in COVID-19 cases

India faces a rise in Covid-19 cases. The Health Ministry advises avoiding crowds and maintaining hygiene. Technical reviews and preparedness measures are underway. Surveillance for ILI and SARI has increased. Testing and genome sequencing are in progress. States are instructed to ensure resource availability. Mock drills are planned to assess oxygen supply. Individuals with respiratory illness should self-monitor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8937XDt
via IFTTT

Read More

Murae Organisor board to consider bonus issue, dividend payout next week

Murae Organisor's board will convene on June 13 to deliberate on a bonus issue of equity shares and dividend payment for FY25. The company is also eyeing strategic business expansion, including investments in agro and distillery sectors. Furthermore, Murae Organisor has set June 11 as the record date for its 1:2 stock split, reporting a revenue of Rs 854.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MWJ9itr
via IFTTT

Read More

IIT Delhi and AIIMS Delhi to establish AI centre for healthcare with Rs 330 crore grant

IIT Delhi and AIIMS Delhi have partnered to establish a Centre of Excellence for Artificial Intelligence in Healthcare (AI-CoE), supported by a ₹330 crore government grant. The centre aims to develop AI-driven solutions to enhance healthcare access and delivery across India, focusing on key national health programs. This initiative seeks to improve healthcare quality for remote and marginalized populations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J0b736o
via IFTTT

Read More

Ujjain to host Spiritual & Wellness Summit, showcasing India’s holistic future

Ujjain is set to host the Spiritual & Wellness Summit on June 5, drawing spiritual leaders, wellness experts, and policymakers. Madhya Pradesh Chief Minister Mohan Yadav will inaugurate the summit, highlighting Ujjain's spiritual legacy. Panel discussions will explore collaborative frameworks harmonizing traditional health systems with modern wellness innovations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tLrB8HU
via IFTTT

Read More

Biocon gets CDSCO nod for generic diabetes medication

Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Type 2 Diabetes in adults and children over 10. CEO Siddharth Mittal highlighted the importance of this vertically integrated GLP-1 drug in expanding access for diabetes patients in India, where cases are rapidly increasing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IeX23DK
via IFTTT

Read More

Medical representatives banned from visiting doctors in govt hospitals

The central government has banned medical representatives from directly meeting doctors in government hospitals to curb unethical practices and potential conflicts of interest. This decision aims to ensure doctors dedicate their time to patient care rather than promotional activities. The government encourages digital communication for sharing treatment advancements, reinforcing efforts to regulate pharmaceutical marketing practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wW5NqBd
via IFTTT

Read More

Glenmark’s blood cancer drug ISB 2001 shows promising results in trial

Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating a 79% overall response rate in a Phase 1 study. The drug targets two sites on the tumor cell and engages the body's T-cells, offering hope for patients who have exhausted other treatment options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xBID9qW
via IFTTT

Read More

Sanofi buys US biopharma group Blueprint in $9.1 billion deal

Sanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt, a drug for systemic mastocytosis. The acquisition also includes elenestinib and BLU-808, expanding Sanofi's pipeline. Blueprint shareholders will receive $129.00 per share in cash, plus contingent value rights for potential milestone payments related to BLU-808's development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S4WKIsZ
via IFTTT

Read More

Apollo Hospitals plans to sell maternity care arm

Apollo Hospitals Enterprises is planning to divest its maternity and infant care chain, Apollo Cradle and Children's Hospital (ACCHL). Allegro Capital has been appointed to find a buyer for ACCHL, with an estimated valuation of ₹1,000-1,200 crore. The sale process is underway, targeting leading private equity funds amidst a growing mother and child care market in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/az9KyWd
via IFTTT

Read More

Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal

Sun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its specialty business. The company will launch Unloxcyt and Leqselvi, while seeking a partner for MM-II development. Sun Pharma anticipates mid-to-high single-digit consolidated topline growth for FY26 and expects R&D spending to be 6-8% of sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2firuNT
via IFTTT

Read More

US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older

Moderna's updated COVID-19 vaccine has received FDA approval for individuals aged 65 and older, marking the first endorsement under stricter regulatory guidelines. The vaccine is also authorized for those between 12 and 64 who have underlying health conditions that increase their risk. This approval signifies a step forward in protecting vulnerable populations against COVID-19.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9yvQmZ5
via IFTTT

Read More

Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch

Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide in India. Semaglutide is the active ingredient in Wegovy. The court has restrained the Indian companies from selling the drug domestically. However, they can still manufacture and export it. The next hearing is scheduled for August 19.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E8VAw19
via IFTTT

Read More

Daiichi comments continue to damage interests: IHH Unit

Northern TK Venture, a subsidiary of IHH Healthcare, has increased its legal claim against Daiichi Sankyo. The claim is now for ₹11,800 crore. NTK alleges Daiichi Sankyo blocked its 2018 open offer for Fortis Healthcare. Daiichi Sankyo denies these claims. NTK seeks damages and an injunction against Daiichi Sankyo's statements. The next court hearing is scheduled for July 11.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lSzYPwn
via IFTTT

Read More

Fortis Open Offer: Daiichi Sankyo's 'misleading' statements continue to damage interests, says NTK

IHH Healthcare's subsidiary, NTK, accuses Daiichi Sankyo of damaging its interests through misleading statements regarding the Fortis Healthcare open offer. NTK has increased its damages claim against Daiichi Sankyo to JPY 200 billion, alleging obstruction of the open offer's completion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gBNxZ4I
via IFTTT

Read More

Flush expired, unused opioids down the toilet, says regulator

Drug regulatory authority mandates disposal of unused opioid drugs and painkillers. This action aims to prevent misuse and health risks. Central Drugs Standard Control Organisation has listed 17 harmful medicines for disposal. Some drugs should be flushed, while others can be collected through 'drug take back' programs. Unscientific disposal causes environmental pollution and drug resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i4SOdIp
via IFTTT

Read More

India gears up to reboot ICU standards, fix doctor drain, and cash in on global med travel

India is developing a structured critical care framework to bridge infrastructure and human resource gaps. Led by NITI Aayog, the initiative will define resource allocation, patient prioritization, and standards for critical care units nationwide. This aims to improve domestic healthcare and attract medical tourists, addressing current imbalances and talent drain while preparing for future health crises.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYsk1yx
via IFTTT

Read More

Novartis offers payment plan for high-cost heart medicine

Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden access by offering zero-interest EMI options. This strategy addresses the drug's high cost, previously ₹1.2 lakh per injection, and involves partnerships with Mankind Pharma, JB Pharma, and Lupin to expand market reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uDFQsO8
via IFTTT

Read More

Quadria's third fund nets $1 billion, to deploy 60% in India

Quadria Capital, an Asia healthcare-focused private equity firm, has successfully raised $1.07 billion for its third fund, surpassing its initial $800 million target. The oversubscribed fund will allocate approximately 60% of its capital to India, with the remainder invested in ASEAN countries. This fund also marks the first time Quadria Capital has received significant domestic capital commitments from Indian institutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3tM7RZD
via IFTTT

Read More

Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America

Lupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding Mexico and Argentina, is the target. SteinCares will handle regulatory aspects. Lupin will manufacture the biosimilar drug. This collaboration aims to improve retinal care access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KxY4EqD
via IFTTT

Read More

VC funding, influencers power India’s health supplements craze amid lingering safety concerns

Fast forward to 2025, and a whole new market has emerged — gummies to enhance your hair health, powders to boost collagen, liquid for gut, pills for women’s perimenopause hormonal imbalance, magnesium tablets for better sleep, testosterone boosters, capsules with calming properties and vegan versions of all these.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/36WlDMp
via IFTTT

Read More

Dr Reddy's gets 2 observations from USFDA for Telangana API plant

Dr. Reddy's Laboratories received a Form 483 with two observations following a GMP inspection by the USFDA at its API manufacturing plant (CTO-5) in Miryalaguda, Telangana. The inspection, conducted from May 19 to May 24, 2025, identified potential violations of the Food Drug and Cosmetic Act. The company plans to address the concerns within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HnPdDcN
via IFTTT

Read More

China’s India Headache: The growing pharmaceutical industry

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desire to diversify from China. These companies are investing in advanced technologies and specialized capabilities, particularly in biologics and complex chemistry, to capture a larger share of the global market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hSyN8pX
via IFTTT

Read More

Venus Remedies gets Ukrainian GMP renewal certification

Venus Remedies has received renewed GMP certification from Ukraine. This certification applies to its Baddi facility. It covers cephalosporin, non-cephalosporin, and oncology production lines. The company aims to strengthen its presence in Ukraine and PIC/S markets. This will facilitate international growth. The Ukrainian pharmaceutical market is expected to grow. Venus Remedies plans to expand its product portfolio in the region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c9XkWqi
via IFTTT

Read More

Waive risk-based inspections, urges MSME pharma body

Laghu Udyog Bharati requests the government to waive risk-based inspections for companies upgrading their facilities. The association seeks an extension for Schedule M implementation for smaller firms. Concerns arise over inspections being conducted like raids. LUB highlights the role of MSMEs in supplying medicines during Covid. They request special attention for manufacturers with less than Rupees 50 crore turnover.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wdtkQ0B
via IFTTT

Read More

Sun Pharma to invest $25 mn in Pharmazz Inc; raises stake to 22.7 pc

Sun Pharmaceutical Industries Ltd will invest up to USD 25 million in Pharmazz Inc, increasing its stake to 22.7%. This investment triggers the conversion of a previous agreement. Sun Pharma gains an option to negotiate licensing of Sovateltide for developed markets and already holds exclusive rights for emerging markets. Pharmazz is developing drugs for stroke and hypovolemic shock.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4Rb8yNH
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic high blood pressure treatment drug

Alembic Pharmaceuticals announced that it has secured final approval from the USFDA for its generic amlodipine and atorvastatin tablets, used for treating hypertension. The approval covers multiple strengths of the tablets, therapeutically equivalent to Pharmacia and Upjohn Co LLC's Caduet. With this approval, Alembic now has a cumulative total of 223 ANDA approvals from the USFDA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LOfTUnE
via IFTTT

Read More

Zydus working on single pen device for adjustable Semaglutide doses

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It targets both diabetes and obesity. Clinical trials are underway in India. Zydus plans a day 1 launch in India. They will explore partnerships for emerging markets. The device aims to improve patient convenience. Some companies have shown interest in co-marketing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SK1XwPD
via IFTTT

Read More

Many MSME pharma firms making substandard drugs, CDSCO data shows

Data from the CDSCO reveals that numerous MSME pharmaceutical companies in India are producing substandard drugs, failing to meet safety standards. Inspections have uncovered issues with infrastructure, quality management, and manufacturing processes. A significant percentage of MSMEs have faced stop production orders due to these quality concerns, prompting calls for stricter GMP regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RV0IqHS
via IFTTT

Read More

Neuberg, Star Imaging in joint venture to expand integrated diagnostics across Maharashtra

Neuberg Diagnostics and Star Imaging have partnered to expand integrated diagnostic centers across Maharashtra, aiming to unify radiology, pathology, wellness, and genomics for improved accuracy and faster diagnoses. This joint venture will establish a comprehensive, technologically advanced network, launching new centers in key cities like Pune and Nagpur over the next two years, ensuring accessible and affordable healthcare diagnostics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xy3v856
via IFTTT

Read More

Bharat Biotech's cholera vaccine successfully completes Phase-III trials

Bharat Biotech's oral Cholera Vaccine, Hillchol, has successfully completed phase III clinical trials, demonstrating non-inferiority against Ogawa and Inaba serotypes in Indian adults and children. The study involved 1,800 participants across various age groups and ten clinical sites in India. With a production capacity of 200 million doses, Hillchol aims to address the global OCV shortage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fBnxjT1
via IFTTT

Read More

Aman Mehta appointed Managing Director of Torrent Pharma

Torrent Pharmaceuticals has appointed Aman Mehta, son of current chairman Samir Mehta, as Managing Director, effective August 1, 2025. This move marks the third-generation leadership taking charge, building upon the legacy of founder Uttambhai Nathalal Mehta. Aman's experience includes successful integration of acquisitions and strategic roles across Torrent Group's diverse sectors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JGK1Igh
via IFTTT

Read More

IHH Healthcare increases damages claim against Daiichi Sankyo to Rs 11,800 cr over Fortis acquisition dispute

IHH Healthcare's indirect subsidiary, Northern TK Venture Pte Ltd, has significantly increased its damages claim against Daiichi Sankyo to approximately Rs 11,800 crore. This revision follows Daiichi Sankyo's alleged interference with IHH's bid to acquire a larger stake in Fortis back in 2018. The increased claim accounts for losses and reputational harm, with the next hearing set for July 11.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VTI7hd0
via IFTTT

Read More

Domestic drug companies in a sweet spot as global players look beyond insulin

Indian drug companies are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin and more type 1 diabetes cases are helping them. Domestic companies accounted for 25% of the market. Multinational companies are shifting focus. This shift creates opportunities for Indian companies. Lupin acquired Huminsulin brand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vwOYf2M
via IFTTT

Read More

India's orthopaedic and cardiac implant sector to touch $4.5-5 bn by FY28: Report

India's implant sector is set for significant growth. The orthopaedic and cardiac implant market may hit USD 5 billion by FY28. Domestic manufacturers are expanding rapidly. They are outpacing foreign companies. Government initiatives and healthcare improvements are fueling this surge. Zydus Lifesciences and Alkem Laboratories are investing in this sector. The industry is moving towards self-reliance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j71uVvW
via IFTTT

Read More

Non-AI organisations won't make it to 2050, says Diogo Rau

Eli Lilly's Diogo Rau emphasizes the critical role of AI in the pharmaceutical industry's future, predicting that companies not investing in AI now may not survive by 2050. Rau highlights AI's potential in drug discovery, including designing proteins and identifying promising molecules. He notes the challenge of limited datasets and the importance of negative results in training AI models.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9gIOD5M
via IFTTT

Read More

Dr Reddy's gets 2 observations from USFDA for New York API plant

Dr. Reddy's Laboratories announced that the USFDA issued a Form 483 with two observations after a GMP inspection of its API manufacturing facility in Middleburgh, New York. The inspection, conducted between May 12-16, 2025, identified potential violations of the Food Drug and Cosmetic Act.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pfM1h8q
via IFTTT

Read More

'Irrational' fixed dose combos harmful, may face ban: Expert panel

Several personal care products containing ingredients like aloe vera, jojoba oil, and orange oil are likely to be banned in India. An expert committee has deemed these fixed-dose combinations (FDCs) as irrational and potentially harmful to human health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ofjYH2
via IFTTT

Read More

Piramal Pharma to stay away from prescription business in India: Nandini Piramal

Piramal Pharma is not planning to re-enter the domestic prescription formulations business, according to chairperson Nandini Piramal. Instead, the company will focus on its consumer healthcare business, potentially acquiring OTC portfolios or brands, and explore targets in its global complex hospital generics business. Piramal Pharma will continue organic expansion in its CDMO business with a capex of $100-125 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gYsHVpO
via IFTTT

Read More

Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: Report

A report suggests Indian generic drug companies may not be affected by US President Donald Trump's order. The order aims to lower US prescription drug prices. It will match them to those of other developed nations. The 'Most-Favoured-Nation' price model will be introduced. This model will cover Medicare and Medicaid. The order may face legal challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5yvpVTa
via IFTTT

Read More

Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran Shaw

Biocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity, aiming to improve profitability. The company is also considering a merger with its parent company as an alternative to an IPO due to market uncertainties.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iaU2g47
via IFTTT

Read More

Revolutionary Non-Surgical Hair Growth Treatment by Dr. Stuti Khare Shukla - Consult Online Worldwide

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ri5tOV2
via IFTTT

Read More

Donald Trump’s order to lower prices may benefit generics, says Cipla CEO

Cipla anticipates that Donald Trump's order to lower US drug prices could favor generic drug companies like itself. The company reported a strong Q4 performance with a 30% increase in net profit. Cipla is optimistic about growth in India, particularly in the weight-loss drug market, and is exploring both organic and inorganic expansion opportunities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jPevCId
via IFTTT

Read More

US govt order to have nil impact on Indian pharma players, says Cipla

Umang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug prices are already competitive. Vohra also states that potential US tariffs on pharmaceutical imports are not expected to significantly impact Cipla's business. He mentions that discussions between the US and Indian governments are ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CQaIBbU
via IFTTT

Read More

Lupin launches generic version of kidney disorder treatment drug in US

Lupin Ltd has launched generic Tolvaptan tablets in the US, after receiving USFDA approval. These tablets, with strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, are bioequivalent to Jynarque and indicated for slowing kidney function decline in adults with ADPKD. Lupin holds exclusive first-to-file status, granting them 180-day generic drug exclusivity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mp5Ryax
via IFTTT

Read More

Trump drops the price bomb, Indian pharma may feel aftershock

President Trump's plan to lower US prescription drug prices by aligning them with other countries could impact Indian pharmaceutical companies, which heavily rely on the US market for revenue. While primarily targeting innovator drugmakers, the move may squeeze Indian generic firms, potentially leading to margin pressure and strategic adjustments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bULETZg
via IFTTT

Read More

India has not accepted 'data exclusivity' demand by UK to protect generic drug firms

India has declined the UK's request for a 'data exclusivity' clause in their free trade agreement to safeguard its domestic generic drug industry. This decision mirrors a previous rejection of a similar demand from the EFTA bloc. The move aims to protect the flourishing generic drug sector, a key player in India's exports, from potential restrictions on producing affordable medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/71ebJdW
via IFTTT

Read More

Trump's drug order sparks concern for India's pharma policy: GTRI

Donald Trump's "Most Favored Nation" pricing rule, aimed at significantly lowering U.S. drug prices, is expected to have global repercussions. The move could pressure pharmaceutical companies to seek higher revenues in markets like India, potentially impacting its pharmaceutical policies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UXRAgN4
via IFTTT

Read More

Biocon plans $150-million capex in two years

Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 million to generics. Fueled by strong generics growth and biosimilar progress, Q4 net profit surged 153%. The company launched key medications in the US and UK, focusing on peptide portfolios and biosimilars for future growth, with analysts maintaining a positive outlook.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WvP9ASY
via IFTTT

Read More

Dr. Reddy's eyes aspirational goal to be in top five in the Indian market

Dr. Reddy's Laboratories is prioritizing innovative product launches through strategic partnerships to achieve a 15-16% growth in the Indian market. The company's focus includes expanding its portfolio with new products, growing existing brands, and strengthening its consumer health segment. Recent successes include the launch of toripalimab and upcoming respiratory vaccine and allergy product launches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7yYGrU
via IFTTT

Read More

FDC recalls over 60,000 bottles of ophthalmic solution in US

FDC Ltd is recalling over 60,000 bottles of Timolol Maleate Ophthalmic Solution, a generic glaucoma medication, in the US market. The USFDA reported the recall, initiated on April 18, is due to a defective container issue where the bottle's spike was lodged in the nozzle, preventing solution dispensing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IVYDQ0k
via IFTTT

Read More

Zydus gets USFDA nod for generic drug to treat multiple sclerosis

Zydus Lifesciences has secured USFDA approval to market Glatiramer Acetate Injection, a generic version of Copaxone, for treating relapsing forms of Multiple Sclerosis. Developed with Chemi S.p.A. and manufactured in Europe, the drug addresses a market with USD 719 million in annual sales in the US. This approval highlights Zydus' dedication to providing diverse therapeutic options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8K9ibp7
via IFTTT

Read More